title: Infliximab-related malignant melanoma and cranial nerves IX and XII palsy secondary to IFN-α2b therapy.
authors: From the Departments of Dermatology, Otolaryngology, and Oncology, University Hospital of Salamanca, Paseo de San Vicente, Salamanca, Spain.
authors: José M
authors: JM
authors: Mir-Bonafé
authors: Emilia
authors: E
authors: Fernández-López
authors: Javier
authors: J
authors: Cañueto
authors: María
authors: M
authors: Gil-Melcón
authors: Rocío
authors: R
authors: García-Domínguez
authors: Pablo
authors: P
authors: de Unamuno-Pérez
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003389:Cranial Nerve Diseases / Q000139:chemically induced*; D005930:Glossopharyngeal Nerve; D017497:Hidradenitis Suppurativa / Q000188:drug therapy*; D006801:Humans; D007002:Hypoglossal Nerve; D000069285:Infliximab; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000139:chemically induced*; D008875:Middle Aged; D009669:Nose Neoplasms / Q000139:chemically induced*; D011994:Recombinant Proteins / Q000009:adverse effects
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D000069285:Infliximab